Combination therapy of oAd/IL12/GM-RLX with αPD1 increased the proportions of intratumoral CD8+, IFN-γ+ and CD8+, PFRN+ T cells, leading to a durable suppression of tumor growth. Here, CD8A is linked to neoplasm.